Provided by Tiger Fintech (Singapore) Pte. Ltd.

Olema Pharmaceuticals, Inc.

4.74
+0.32147.27%
Volume:692.38K
Turnover:3.24M
Market Cap:323.99M
PE:-2.15
High:4.82
Open:4.38
Low:4.31
Close:4.42
Loading ...

Promising Outlook for Olema Pharmaceuticals: Buy Rating Affirmed Amid Strategic Positioning in ER+ Breast Cancer Treatment

TIPRANKS
·
14 Apr

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 Apr

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
03 Apr

Olema Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
28 Mar

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

GlobeNewswire
·
26 Mar

North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs

Dow Jones
·
21 Mar

Analysts Are Bullish on Top Healthcare Stocks: Integer Holdings (ITGR), Olema Pharmaceuticals (OLMA)

TIPRANKS
·
20 Mar

Olema Pharmaceuticals Price Target Cut to $25.00/Share From $30.00 by Oppenheimer

Dow Jones
·
20 Mar

Olema Pharmaceuticals, Inc. : Oppenheimer Cuts Target Price to $25 From $30

THOMSON REUTERS
·
19 Mar

Olema Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
19 Mar

Promising Clinical Data and Market Opportunities Drive Buy Rating for Olema Pharmaceuticals

TIPRANKS
·
19 Mar

Oppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
19 Mar

Olema Pharmaceuticals Q4 Net Loss Widens

MT Newswires Live
·
19 Mar

Olema Pharmaceuticals Q4 2024 GAAP EPS $(0.51) Beats $(0.63) Estimate

Benzinga
·
19 Mar

BRIEF-Olema Oncology Q4 Net Income USD -33.567 Million

Reuters
·
19 Mar

Olema Oncology Q4 Income From Operations USD -36.768 Million

THOMSON REUTERS
·
19 Mar

Press Release: Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Dow Jones
·
19 Mar

Olema Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
17 Mar

Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Mar

Promising Efficacy of Olema Pharmaceuticals’ Palazestrant Supports Buy Rating

TIPRANKS
·
11 Mar